Evidence map›Paper›PMID 36912550›Full record

ArticleJournal of visualized experiments : JoVE2023

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays.

Lillian van Biljon, Bisiayo Fashemi, Jeimmy Rodriguez, Olivia Graham, Amanda Compadre, Katherine Fuh, Dineo Khabele, Mary Mullen

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lillian van BiljonWashington University in St. Louis.
Bisiayo FashemiWashington University in St. Louis.
Jeimmy RodriguezWashington University in St. Louis.
Olivia GrahamWashington University in St. Louis.
Amanda CompadreWashington University in St. Louis.
Katherine FuhWashington University in St. Louis; University of California San Francisco.
Dineo KhabeleWashington University in St. Louis.
Mary MullenWashington University in St. Louis; marymullen@wustl.edu.
Washington University in St. Louis · USUniversity of California, San Francisco · US

Funding

Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer - Diversity SupplementR01CA243511 · NCI · WASHINGTON UNIVERSITY · PI KHABELE, DINEO · 2020 to 2024
$2.5M
NCI NIH HHS R01 CA243511
6 · The paper itself

Abstract

Immunofluorescence is one of the most widely used techniques to visualize target antigens with high sensitivity and specificity, allowing for the accurate identification and localization of proteins, glycans, and small molecules. While this technique is well-established in two-dimensional (2D) cell culture, less is known about its use in three-dimensional (3D) cell models. Ovarian cancer organoids are 3D tumor models that recapitulate tumor cell clonal heterogeneity, the tumor microenvironment, and cell-cell and cell-matrix interactions. Thus, they are superior to cell lines for the evaluation of drug sensitivity and functional biomarkers. Therefore, the ability to utilize immunofluorescence on primary ovarian cancer organoids is extremely beneficial in understanding the biology of this cancer. The current study describes the technique of immunofluorescence to detect DNA damage repair proteins in high-grade serous patient-derived ovarian cancer organoids (PDOs). After exposing the PDOs to ionizing radiation, immunofluorescence is performed on intact organoids to evaluate nuclear proteins as foci. Images are collected using z-stack imaging on confocal microscopy and analyzed using automated foci counting software. The described methods allow for the analysis of temporal and special recruitment of DNA damage repair proteins and colocalization of these proteins with cell-cycle markers.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsCell LineDNA DamageFemaleHumansOrganoidsTumor Microenvironment

Identifiers

PMID36912550
PMCPMC10881227
OpenAlexW4321763825

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.